Table 1 The demographics and clinical characteristics of anti-NMDAR encephalitis in the training and validation cohorts
Characteristics | Derivation cohort (n = 107) | Validation cohort (n = 59) | p-value |
|---|---|---|---|
Gender, Male | 47 (43.93) | 29 (49.15) | 0.518 |
Age | 13 (2–72) | 26 (2–78) | < 0.001 |
Prodromal symptoms | 40 (37.38) | 21 (35.59) | 0.819 |
Clinical manifestations | Â | Â | Â |
 Abnormal behavior or cognitive dysfunction | 87 (81.31) | 45 (76.27) | 0.441 |
 Speech dysfunction | 49 (45.79) | 5 (8.47) | < 0.001 |
 Seizures | 83 (77.57) | 42 (71.19) | 0.361 |
 Movement disorder | 64 (59.81) | 14 (23.73) | < 0.001 |
 Consciousness impairment | 19 (17.76) | 7 (11.86) | 0.393 |
 Autonomic dysfunction or central hypoventilation | 18 (16.82) | 7 (11.86) | 0.393 |
auxiliary examination | Â | Â | Â |
 CSF pleocytosis | 38 (35.51) | 30 (50.85) | 0.054 |
 Elevated CSF protein | 21 (19.63) | 16 (27.12) | 0.267 |
 Abnormal MRI | 47 (43.93) | 24 (40.68) | 0.686 |
 Abnormal EEG | 85(79.44) | 52 (88.14) | 0.158 |
Tumor | 4 (3.74) | 6 (10.17) | 0.096 |
Early immunotherapy | 82 (76.64) | 40 (67.80) | 0.273 |
Poor prognosis | 46 (42.99) | 25 (42.37) | 0.939 |